MedTrace Logo

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

NCT06094556 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-04-13

No results posted yet for this study

Summary

This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.

Conditions

Interventions

DRUG

SHR-1826

dose is calculated based on the subjects' baseline weight.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-25
Primary Completion
2027-06-30
Completion
2027-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06094556 on ClinicalTrials.gov